Corcept Therapeutics Incorporated
NASDAQ:CORTBiotechnology
-$1.96 today
- Market cap
- $7.42B
- Beta
- 0.50
- P/E (TTM)
- 178.2
- EPS (TTM)
- $0.46
Volume 0.74M
Average 1.41M
CORT EBITDA Margin
EBITDA as a percentage of revenue.
Corcept Therapeutics IncorporatedNASDAQ: CORT
EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026
EBITDA Margin widens to 18.3%
EBITDA Margin was 18.3% in Q2 FY2026, up 1.7 pp from a year earlier. On a trailing-twelve-month basis it was 3.5%, down 14.4 pp year over year. Over 3 fiscal years it narrowed by 20.8 pp.
Context
- EBITDA Margin widened in 0 of the last 3 fiscal years.
- FY2025 was the lowest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 3 analysts of 27.8% for the fiscal year ending Dec 2026, up from 9.0% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- 18.3%+45.0 pp QoQ
- Last fiscal yearDec 2025
- 9.0%-15.1 pp YoY
- LTMJun 2026
- 3.5%-14.4 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 9.0%
- Year-over-year change
- -15.1pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.0% | -15.1pp |
| FY2024 | 2024-12-31 | 24.1% | -2.2pp |
| FY2023 | 2023-12-31 | 26.3% | -3.5pp |
| FY2022 | 2022-12-31 | 29.8% | -5.2pp |
| FY2021 | 2021-12-31 | 35.0% | — |
EBITDA Margin vs competitors
How CORT compares with its peers on the latest reported figures
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 3.5% | -14.4 pp | -20.8 pp | |
MBXMBX Biosciences, Inc. Common Stock | FY2025 | — | — | — |
| FY2025 | — | — | — | |
| Peer median (excluding CORT) | — | — | — | |
Competitors are the stored peer set for CORT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 365.98M | 401.86M | 482.38M | 675.04M | 761.41M |
| Cost of Revenue | 5.28M | 5.39M | 6.48M | 10.88M | 12.98M |
| Gross Profit | 360.7M | 396.47M | 475.89M | 664.16M | 748.43M |
| Gross Margin | 98.6% | 98.7% | 98.7% | 98.4% | 98.3% |
| Research & Development | 113.86M | 130.99M | 184.35M | 246.89M | 254.91M |
| Selling, General & Admin | 122.36M | 152.85M | 184.26M | 280.32M | 448.73M |
| Operating Expenses | 236.22M | 283.84M | 368.61M | 527.21M | 703.63M |
| Depreciation & Amortization | 3.07M | 3.45M | 2.36M | 1.34M | 1.89M |
| EBITDA | 127.95M | 119.64M | 126.92M | 162.83M | 68.35M |
| EBITDA Margin | 35.0% | 29.8% | 26.3% | 24.1% | 9.0% |
| Operating Income | 124.48M | 112.63M | 107.28M | 136.95M | 44.8M |
| Operating Margin | 34.0% | 28.0% | 22.2% | 20.3% | 5.9% |
| Interest Income | 529K | 3.56M | 17.28M | 24.54M | 21.67M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 529K | 3.56M | 17.28M | 24.54M | 21.67M |
| Income Before Tax | 125.01M | 116.19M | 124.56M | 161.49M | 66.46M |
| Pre-Tax Margin | 34.2% | 28.9% | 25.8% | 23.9% | 8.7% |
| Income Tax Expense | 12.49M | 14.77M | 18.42M | 20.28M | (33.19M) |
| Net Income | 112.51M | 101.42M | 106.14M | 139.73M | 99.65M |
| Net Margin | 30.7% | 25.2% | 22.0% | 20.7% | 13.1% |
| EPS (Basic) | 0.97 | 0.95 | 1.02 | 1.35 | 0.95 |
| EPS (Diluted) | 0.89 | 0.87 | 0.94 | 1.23 | 0.82 |
| Weighted Avg Shares | 115.65M | 106.79M | 103.56M | 103.23M | 103.86M |
| Weighted Avg Shares (Diluted) | 125.96M | 115.97M | 111.74M | 113.48M | 119.99M |
Corcept Therapeutics Incorporated
NASDAQ:CORT
Intrinsic Alpha fair value
Locked
Current Price
$67.79
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.